Aubagne, January 1, 2023

Half-year liquidity contract statement for Sartorius Stedim Biotech

Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2022:

• 11,901 shares
• € 6,837,423.41
• Number of executions on buy side on semester: 4,259
• Number of executions on sell side on semester: 4,361
• Traded volume on buy side on semester: 166,507 shares for € 56,282,984.47
• Traded volume on sell side on semester: 174,847 shares for € 59,810,740.92

As a reminder, the following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:

• 20,241 shares
• € 3,286,293.04
• Number of executions on buy side on semester: 4,639
• Number of executions on sell side on semester: 4,205
• Traded volume on buy side on semester: 186,508 shares for € 64,215,074.25
• Traded volume on sell side on semester: 169,628 shares for € 57,532,559.42

The following resources appeared on the liquidity account when the activity started:

• 0 shares
• € 10,000,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, the shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.

Contact

Petra Müller

Head of Investor Relations

+49 (0)551.308.6035

Petra.mueller2@sartorius.com

Sartorius Stedim Biotech S.A.

Z.I. Les Paluds

Avenue de Jouques, CS 91051

13781 Aubagne Cedex, France

Phone: +33.(0)4.42.84.56.00

Fax: +33.(0)4.42.84.56.19

www.sartorius.com